Ambulatory Blood Pressure Monitoring–Derived Short‐Term Blood Pressure Variability in Primary Aldosteronism

The aim of this study was to investigate the short‐term blood pressure (BP) variability (BPV) derived from ambulatory blood pressure monitoring (ABPM) in patients with primary aldosteronism (PA), either idiopathic hyperaldosteronism (IHA) or aldosterone‐producing adenoma (APA), in comparison with patients with essential hypertension (EH) and normotensive (NT) controls. Thirty patients with PA (16 with IHA and 14 with APA), 30 patients with EH, and 30 NT controls, matched for sex, age, body mass index, and antihypertensive therapy, were studied. The standard deviation (SD) of 24‐hour, daytime, and nighttime BP; 24‐hour weighted SD of BP; and 24‐hour BP average real variability were not different between patients with PA and those with EH (P=not significant). All BPV indices were higher in patients with PA, either IHA or APA subtypes, and patients with EH, compared with NT controls (P<.001 to P<.05). ABPM‐derived short‐term BPV is increased in patients with PA, and it may represent an additional cardiovascular risk factor in this disease. The role of aldosterone excess in BPV has to be clarified.

[1]  J. Zicha,et al.  Obesity-related hypertension: possible pathophysiological mechanisms. , 2014, The Journal of endocrinology.

[2]  G. Parati,et al.  Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension , 2014, Hypertension Research.

[3]  N. Sonino,et al.  Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing’s syndrome , 2014, Endocrine.

[4]  G. Parati,et al.  Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes , 2013, Diabetes Care.

[5]  T. Zelinka,et al.  Vascular Disturbances in Primary Aldosteronism: Clinical Evidence , 2012, Kidney and Blood Pressure Research.

[6]  G. Mancia Short- and long-term blood pressure variability: present and future. , 2012, Hypertension.

[7]  C. Pilon,et al.  Primary Aldosteronism and Metabolic Syndrome , 2011, Hormone and Metabolic Research.

[8]  G. Fava,et al.  Psychological assessment of primary aldosteronism: a controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  Alessandro Squizzato1 , 2,et al.  The Influence of Pituitary, Adrenal, and Parathyroid Hormones on Hemostasis and Thrombosis , 2011, Seminars in thrombosis and hemostasis.

[10]  P. Fesler,et al.  Dietary Sodium, Aldosterone, and Left Ventricular Mass Changes During Long-Term Inhibition of the Renin-Angiotensin System , 2010, Hypertension.

[11]  S. Nesbitt,et al.  Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  E. O’Brien,et al.  Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke , 2010, The Lancet Neurology.

[13]  M. Stowasser,et al.  Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism , 2010, Hypertension.

[14]  Marta Di Nicola,et al.  Prognostic value of different indices of blood pressure variability in hypertensive patients. , 2009, American journal of hypertension.

[15]  Y. Toya,et al.  Identification of an Increased Short-Term Blood Pressure Variability on Ambulatory Blood Pressure Monitoring as a Coronary Risk Factor in Diabetic Hypertensives , 2009, Clinical and experimental hypertension.

[16]  W. Young,et al.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  L. Sechi,et al.  Cardiovascular outcomes in patients with primary aldosteronism after treatment. , 2008, Archives of internal medicine.

[18]  G. Parati,et al.  A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall , 2007, Journal of hypertension.

[19]  S. Liatis,et al.  Sympathetic System Activity in Obesity and Metabolic Syndrome , 2006, Annals of the New York Academy of Sciences.

[20]  G. Regolisti,et al.  Comparison of confirmatory tests for the diagnosis of primary aldosteronism. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  M. Ermani,et al.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. , 2006, The Journal of clinical endocrinology and metabolism.

[22]  P. Milliez,et al.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.

[23]  Salvador A. Pintos,et al.  A reliable index for the prognostic significance of blood pressure variability , 2005, Journal of hypertension.

[24]  T. Thrasher,et al.  Baroreceptors and the long‐term control of blood pressure , 2004, Experimental physiology.

[25]  F. Veglio,et al.  Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism , 2002, Hypertension.

[26]  M. Kikuya,et al.  Prognostic Significance of Blood Pressure and Heart Rate Variabilities: The Ohasama Study , 2000, Hypertension.

[27]  M. Boscaro,et al.  Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  Y. Imai,et al.  Decreased blood pressure variability at rest in patients with primary aldosteronism. , 1998, American journal of hypertension.

[29]  W. White,et al.  Circadian blood pressure variation in hypertensive patients with primary hyperaldosteronism. , 1998, Hypertension.

[30]  J. Krakauer,et al.  Diagnosis and Treatment of Primary Aldosteronism , 1995, Annals of Internal Medicine.

[31]  F. Veglio,et al.  Spectral characteristics of heart rate and blood pressure variability in primary aldosteronism. , 1995, American journal of hypertension.

[32]  B. Kasiske,et al.  Effects of Antihypertensive Therapy on Serum Lipids , 1995, Annals of Internal Medicine.

[33]  O. Tochikubo,et al.  Muscle Sympathetic Nerve Activity in Renovascular Hypertension and Primary Aldosteronism , 1991, Hypertension.

[34]  H. Lithell Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism , 1991, Diabetes Care.

[35]  M. Schalekamp,et al.  Volume‐Pressure Relationships during Development of Mineralocorticoid Hypertension in Man , 1977, Circulation research.

[36]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[37]  R. Tarazi,et al.  Hemodynamic characteristics of primary aldosteronism. , 1973, The New England journal of medicine.

[38]  M. Mcilroy,et al.  Abnormalities of Renal Function and Circulatory Reflexes in Primary Aldosteronism , 1966, Circulation.

[39]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[40]  S. Malpas Neural influences on cardiovascular variability: possibilities and pitfalls. , 2002, American journal of physiology. Heart and circulatory physiology.

[41]  J D Veldhuis,et al.  Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism. , 1995, The Journal of clinical endocrinology and metabolism.

[42]  R. Tarazi,et al.  The sympathetic nervous system and hypertension in primary aldosteronism. , 1985, Hypertension.

[43]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .